While therapeutic efficacy with NKp30-CD137 TCRKO CAR T cells was limited and not durable, adoptive transfer of NKp30-CD28 CAR TCRKO T cells resulted in profound tumor regression. This evidence concerns the gene TNFRSF9 and neoplasm.